(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/crwe_tech.jpg

Your Technology Source, Your Technology Team

Server Maintenance, Web Development, Mobile Application Solutions, SEO Services and more

Contact Us: contact@crwetech.com

www.CRWETech.com

ad2

http://crweworld.com/assets/images/ad/ad4.png

Place Your Ad Here! Advertise your business online on CRWE WORLD. Your Company, product, or service in front of the world!

Contact Us: contact@crweworld.com

www.CRWEWorld.com

ad3

http://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

http://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com

ad5

http://crweworld.com/assets/images/ad/Pathology_Laboratories.png

Quest Diagnostics Inc. (NYSE:DGX) offers the most extensive clinical testing network in the U.S. The Company's extensive test menu includes routine biological testing; complex and specialized molecular and gene-based testing, and anatomic pathology testing. These services primarily help identify disease or risk factors for disease and predict and monitor response to treatment.

www.QuestDiagnostics.com






139 Result: Surgery

Puma Biotechnology Announces Positive PB272 Phase II Data from TBCRC 022 Trial in Patients with HER2-Positive Metastatic Breast Cancer with Brain Metastases at the 2017 ASCO Annual Meeting

June 05th, 2017

LOS ANGELES, Calif. / CRWE PRESS RELEASE / June 3, 2017 - Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced the presentation of positive results from an ongoing Phase II clinical trial (Translational Breast Cancer Resear. Read more

RTI Surgical(R) Partners in New Manufacturing USA Institute

June 02nd, 2017

The Advanced Regenerative Manufacturing Institute (ARMI) will receive nearly $300 million in public-private investment from leading manufacturers, universities, nonprofit organizations and the federal government to develop scalable manufacturing proc. Read more

Bovie Medical Receives 510K Clearance for its J-Plasma(R) Precise Flex Handpiece

May 08th, 2017

The Addition of the J-Plasma® Precise Flex rounds out Bovie Medical’s J-Plasma® offering to include products designed for open and minimally invasive surgical procedures, including laparoscopic and robotic approaches. CLEARWATER, FL . Read more

ASPiRA LABs Announces Provider Status with Medi-Cal Expanding OVA1(R) Access to Over 12 Million Beneficiaries

March 06th, 2017

AUSTIN, Texas / CRWE PRESS RELEASE / March 6, 2017 — ASPiRA LABs, a Vermillion company (NASDAQ: VRML), today announced it has attained out-of-state provider status with Medi-Cal, California’s Medicaid program, for OVA1®/Multivari. Read more

ASPiRA LABs Announces Contracted In-Network Agreement with Blue Cross Blue Shield of Michigan for OVA1(R)

March 01st, 2017

AUSTIN, Texas / CRWE PRESS RELEASE / March 1, 2017 — ASPiRA LABs, a Vermillion company (NASDAQ: VRML), today announced a major contracted agreement with Blue Cross Blue Shield of Michigan for ASPiRA’s U.S. FDA cleared, American Colle. Read more

Pluristem Reports Second Quarter Fiscal 2017 Highlights & Provides Calendar 2017 Outlook

February 13th, 2017

HAIFA, Israel / CRWE PRESS RELEASE / February 13, 2017 - Pluristem Therapeutics Inc. (Nasdaq: PSTI, TASE: PSTI), a leading developer of placenta-based cell therapy products, today reported financial update and corporate and clinical developments for . Read more

EyeGate Pharma Announces Positive Top-line Data from First-in-Human Pilot Trial of Ocular Bandage Gel in Corneal Epithelial Defects

January 30th, 2017

Company Plans to Continue Development with Next Controlled Trial Q2 2017 WALTHAM, Mass. / CRWE PRESS RELEASE / January 30, 2017 - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a specialty pharma. Read more

Pluristem Completes Patient Enrollment in a Large Multinational Phase II Trial in Intermittent Claudication

January 12th, 2017

* Top line results from the 172-patient trial to be reported in early 2018 * Data to support Pluristem’s planned Biologics License Application for marketing approval of PLX-PAD in the U.S. and Europe * 14 million people in the U.S. are treate. Read more

NOVADAQ Announces Preliminary Unaudited Fourth Quarter 2016 Revenue and Issues 2017 Revenue Guidance

January 11th, 2017

Secures up to $60 million in financing from Midcap Financial Toronto, Ontario / CRWE PRESS RELEASE / January 10, 2017 - NOVADAQ Technologies Inc (NASDAQ:NVDQ; TSX:NDQ), the leading provider of proven comprehensive fluorescence . Read more

Puma Biotechnology Presents Results of Biomarker Analysis of Phase II Trial of PB272 in Neoadjuvant Treatment of HER2-Positive Locally Advanced Breast Cancer at the 2016 San Antonio Breast Cancer Symposium

December 07th, 2016

LOS ANGELES, Calif. / CRWE PRESS RELEASE / December 7, 2016 - Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that a biomarker analysis of the NSABP FB-7 Phase II clinical trial of Puma's investigational drug PB. Read more

Topline results of Phase 3 investigational study of VONVENDI(TM) [von Willebrand factor (Recombinant)] meets primary endpoint effectively controlling bleeding and blood loss during surgical procedures

December 02nd, 2016

Results will form the basis of a supplemental new drug application to the U.S. Food & Drug Administration, requesting an expanded indication for VONVENDI Lexington, Mass. – December 2, 2016 – Shire plc (LSE: SHP, NASDAQ: SHPG), the lea. Read more

Shire Granted EU Marketing Authorization of ONIVYDE(R), In Combination With 5-Fluorouracil (5-FU) And Leucovorin (LV), For The Treatment of Metastatic Adenocarcinoma Of The Pancreas in Adult Patients Who Have Progressed Following Gemcitabine-Based Therapy

October 18th, 2016

ONIVYDE, in combination with 5-fluorouracil (5-FU) and leucovorin (LV), is the first and only treatment approved for this patient population based on pivotal Phase 3 data (NAPOLI-1) showing increased overall survival i,ii Dublin, Ireland / CRWE . Read more

Aralez to Acquire From AstraZeneca U.S. Rights to Beta Blocker Toprol-XL(R)

October 04th, 2016

-On an Adjusted EBITDA Basis, Transaction Expected to be EBITDA Accretive and to Move Profitability Forward to 2017- -Company to Host Conference Call on October 4, 2016 at 8:30 a.m. ET- MISSISSAUGA, Ontario / CRWE PRESS RELEASE / October 4, 201. Read more

ConforMIS Announces Sale of Over 50,000 Customized Knee Implants

October 04th, 2016

To Commemorate Milestone, ConforMIS to Host Inaugural Patient Ambassador Summit Bedford, Mass. / CRWE PRESS RELEASE / October 4, 2016 – ConforMIS, Inc. (NASDAQ:CFMS), a medical technology company that develops, manufactures and sel. Read more

Shire's First Prescription Eye Drop, Xiidra(TM) (lifitegrast ophthalmic solution) 5% Is Now Available in the U.S.

August 29th, 2016

Xiidra is the onlyprescription eye drop approved by the U.S. FDA for the treatment of both signs and symptoms of dry eye disease Resources are available to support patients seeking information regarding coverage and savings offers Xiidra is t. Read more

Load More Content